Radioactive tracer may supercharge immunotherapy for metastatic cancers
NCT ID NCT07197671
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 32 times
Summary
This early-stage study tests a radioactive imaging agent called Y-NM600 in people with metastatic cancer who are already taking immunotherapy drugs (anti-PD-1 or anti-PD-L1). The goal is to find a safe dose and see if the agent can help the drugs work better. Up to 60 participants will be followed for about 9 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UW Carbone Cancer Center
RECRUITINGMadison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.